These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 15720188

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.
    Zhang Z, Wang H, Prasad G, Li M, Yu D, Bonner JA, Agrawal S, Zhang R.
    Clin Cancer Res; 2004 Feb 15; 10(4):1263-73. PubMed ID: 14977824
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. MDM2 oncogene as a target for cancer therapy: An antisense approach.
    Wang H, Zeng X, Oliver P, Le LP, Chen J, Chen L, Zhou W, Agrawal S, Zhang R.
    Int J Oncol; 1999 Oct 15; 15(4):653-60. PubMed ID: 10493945
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
    Wang H, Wang S, Nan L, Yu D, Agrawal S, Zhang R.
    Int J Oncol; 2002 Apr 15; 20(4):745-52. PubMed ID: 11894120
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Growth reduction of a xenotransplanted human soft tissue sarcoma by MDM2 antisense therapy via implanted osmotic minipumps.
    Würl P, Bartel F, Meye A, Kappler M, Bache M, Schmidt H, Schönfelder M, Taubert H.
    Int J Oncol; 2002 May 15; 20(5):1087-93. PubMed ID: 11956608
    [Abstract] [Full Text] [Related]

  • 16. p53-independent activities of MDM2 and their relevance to cancer therapy.
    Zhang Z, Zhang R.
    Curr Cancer Drug Targets; 2005 Feb 15; 5(1):9-20. PubMed ID: 15720185
    [Abstract] [Full Text] [Related]

  • 17. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
    Xiong J, Yang Q, Li J, Zhou S.
    Angiogenesis; 2014 Jan 15; 17(1):37-50. PubMed ID: 23907365
    [Abstract] [Full Text] [Related]

  • 18. MDM2 and its splice variant messenger RNAs: expression in tumors and down-regulation using antisense oligonucleotides.
    Bartel F, Harris LC, Würl P, Taubert H.
    Mol Cancer Res; 2004 Jan 15; 2(1):29-35. PubMed ID: 14757843
    [Abstract] [Full Text] [Related]

  • 19. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation.
    Mu Z, Hachem P, Agrawal S, Pollack A.
    Prostate; 2004 Aug 01; 60(3):187-96. PubMed ID: 15176048
    [Abstract] [Full Text] [Related]

  • 20. Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme.
    Prasad G, Wang H, Agrawal S, Zhang R.
    Anticancer Res; 2002 Aug 01; 22(1A):107-16. PubMed ID: 12017271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.